Quizartinib, Ven, Dec in FLT3 ITD Mutated AML
Phase I/II Trial of Quizartinib, Venetoclax, and Decitabine in FLT3-ITD–Mutated AML

Released: December 12, 2023

Activity

Progress
1
Course Completed